Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

Innovation and Market Growth in Brazil

February 10, 2014

Brazil is the first Latin American country to emerge as a global biopharmaceutical collaborator. Hellen Berger reports.

Pharm Exec's Emerging Pharma Leaders 2014 — Nominate Now

February 7, 2014

It's time for you to tell us who you think should receive Pharm Exec's 2014 Emerging Pharma Leadership Award. Read more for details of how to nominate a colleague — or yourself.

Growing Pains: The European Medicines Agency at 20

February 3, 2014

Reflector looks at the growing pains of the European Medicine Agency (EMA) as it faces the key policy challenges of 2014.

Product Positioning 2.0

February 1, 2014

Industry and market transformations have dramatically altered when and how products should be positioned for launch, writes Stan Bernard.

Takeda's Oncology Taskmaster

February 1, 2014

Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge—and a lead position in the hotly contested search to make cancer a treatable disease.

Drug Coverage, Costs Under Scrutiny

February 1, 2014

Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies, writes Jill Wechsler.

Managed Markets: Positioning Your Product For Success with Pull Through Strategies

February 1, 2014

A patient-centric approach to drug development delivers the benefits that actually create value.

The Active Patient: Faces Of Change

February 1, 2014

Advocacy organizations and individual patients are getting more involved in every facet of the healthcare system, from drug R&D, to federal and state policy all fueled by the hour-to-hour passion of living with a disease.

Senior Execs' Anti-Social Media Behavior

January 28, 2014

Recent research says social media and messaging apps are continuing to proliferate. But not so with senior execs, who are starting to avoid these networks altogether, says Chris Molloy.

ADVERTISEMENT

Click here